Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Payables (2020 - 2025)

Insight Molecular Diagnostics' Payables history spans 6 years, with the latest figure at $602000.0 for Q3 2025.

  • For Q3 2025, Payables fell 30.96% year-over-year to $602000.0; the TTM value through Sep 2025 reached $602000.0, down 30.96%, while the annual FY2024 figure was $418000.0, 56.14% down from the prior year.
  • Payables for Q3 2025 was $602000.0 at Insight Molecular Diagnostics, down from $1.3 million in the prior quarter.
  • Across five years, Payables topped out at $4.6 million in Q2 2022 and bottomed at $379000.0 in Q2 2024.
  • The 5-year median for Payables is $1.2 million (2021), against an average of $1.6 million.
  • The largest annual shift saw Payables plummeted 80.83% in 2023 before it surged 236.94% in 2025.
  • A 5-year view of Payables shows it stood at $2.1 million in 2021, then dropped by 12.85% to $1.8 million in 2022, then plummeted by 47.55% to $953000.0 in 2023, then plummeted by 56.14% to $418000.0 in 2024, then skyrocketed by 44.02% to $602000.0 in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Payables are $602000.0 (Q3 2025), $1.3 million (Q2 2025), and $2.3 million (Q1 2025).